MaxCyte, Inc.

MaxCyte, Inc.

Biotechnology

Rockville, Maryland 8,988 followers

Let's Build Better Cells Together

About us

We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

Industry
Biotechnology
Company size
51-200 employees
Headquarters
Rockville, Maryland
Type
Public Company
Founded
1999
Specialties
Vaccine Development, Protein Production, Transfection, Cell Therapy, Gene Therapy, Cancer, Immunotherapy, Electroporation, MyExpertPlatform, Tcell, NKcell, Bispecifics, Gene Editing, Cancer Research, Immuno-oncology, Stem Cell, CARMA, Cell Engineering, Biotechnology, Life Sciences, and Innovation

Locations

  • Primary

    9713 Key West Ave

    Suite 400

    Rockville, Maryland 20850, US

    Get directions

Employees at MaxCyte, Inc.

Updates

Similar pages

Browse jobs

Funding

MaxCyte, Inc. 8 total rounds

Last Round

Series unknown

US$ 1.7M

See more info on crunchbase